Labile iron in cells and body fluids: Physiology, pathology, and pharmacology

Frontiers in Pharmacology

Volumn 5 MAR, Issue , 2014, Pages

  Cabantchik, Zvi Ioav ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Chelator; Fluorescence; Iron; Iron metabolism; Iron overload; Mitochondria; Oxidative stress; Siderophore

Indexed keywords

ANTIOXIDANT; FERRITIN; IRON; LABILE IRON; REACTIVE OXYGEN METABOLITE; TRANSFERRIN; UNCLASSIFIED DRUG;

ASSAY; BODY FLUID; CELL FUNCTION; CELL INFILTRATION; CELL LEVEL; CHELATION; CONCENTRATION (PARAMETERS); ERYTHROCYTE; FLUORESCENCE ANALYSIS; HEMOSIDEROSIS; INTERSTITIAL FLUID; INTESTINE ABSORPTION; IRON BINDING CAPACITY; IRON BLOOD LEVEL; IRON CHELATION; IRON METABOLISM; IRON OVERLOAD; IRON STORAGE; IRON TRANSPORT; LABILE IRON CELL LEVEL; LIVER FUNCTION; OXIDATION REDUCTION POTENTIAL; PH; PLASMA; REVIEW; SPLEEN FUNCTION;

EID: 84897930584     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00045     Document Type: Review

References (74)

1. Arezes, J., Costa, M., Vieira, I., Dias, V., Kong, X. L., Fernandes, R., et al. (2013). Non-transferrin-bound iron (NTBI) uptake by T lymphocytes: evidence for the selective acquisition of oligomeric ferric citrate species. PLoS ONE 8:e79870. doi: 10.1371/journal.pone.0079870.
2. Breuer, W., and Cabantchik, Z. I. (2009). Disorders affecting iron distribution: causes, consequences and possible treatments. Available at: http://www.bloodmed.com/800000/mini-reviews1.asp?id=253&p=1&v=1 (accessed January 6, 2009).
3. Breuer, W., Ermers, M. J., Pootrakul, P., Abramov, A., Hershko, C., and Cabantchik, Z. I. (2001). Deferrioxamine-chelatable iron a component of serum non-transferrin-bound iron used for assessing chelation therapy. Blood 97, 792-798. doi: 10.1182/blood.V97.3.792.
4. Breuer, W., Ghoti, H., Shattat, A., Goldfarb, A., Koren, A., Levin, C., et al. (2012). Non-transferrin bound iron in Thalassemia: differential detection of redox active forms in children and older patients. Am. J. Hematol. 87, 55-61. doi: 10.1002/ajh.22203.
5. Breuer, W., Hershko, C., and Cabantchik, Z. I. (2000). The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus. Sci. 23, 185-191. doi: 10.1016/S0955-3886(00)00087-4.
6. Breuer, W., Shvartsman, M., and Cabantchik, Z. I. (2007). Intracellular labile iron. a review. Int. J. Biochem. Cell Biol. 40, 350-354. doi: 10.1016/j.biocel.2007.03.010.
7. Brissot, P., Ropert, M., Le Lan, C., and Loreal, O. (2012). Non-transferrin bound iron: a key role in iron overload and iron toxicity. Biochim. Biophys. Acta 1820, 403-410. doi: 10.1016/j.bbagen.2011.07.014.
8. Cabantchik, Z. I., Breuer, W., Zanninelli, G., and Cianciulli, P. (2005). LPI-labile plasma iron in iron overload. Best Pract. Res. Clin. Haematol. 18, 277-287. doi: 10.1016/j.beha.2004.10.003.
9. Cabantchik, Z. I., Fibach, E., and Breuer, W. (2009). Can Labile Plasma Iron (LPI) and Labile Cell Iron (LCI) Levels Serve as Early Indicators of Chelation Efficacy in Iron Overload? Available at: http://www.bloodmed.com/800000/mini-reviews1.asp?id=254 (accessed July 14, 2009).
10. Cabantchik, Z. I., Kakhlon, O., Epsztejn, S., Zanninelli, G., and Breuer, W. (2002). Intracellular and extracellular labile iron pools. Adv. Exp. Med. Biol. 509, 55-75. doi: 10.1007/978-1-4615-0593-8_4.
11. Cabantchik, Z. I., Sohn, Y. S., Breuer, W., and Espósito, B. P. (2013). The Molecular and Cellular Basis of Iron Toxicity in Iron Overload Disorders. Diagnostic and Therapeutic Approaches. Thalassemia Reports, 3, 7-13.
12. Cairo, G., and Recalcati, S. (2007). Iron-regulatory proteins: molecular biology and patho-physiological implications. Expert Rev. Mol. Med. 9, 1-13. doi: 10.1017/S1462399407000531.
13. Camaschella, C. (2009). Hereditary sideroblastic anemias: pathophysiology, diagnosis, and treatment. Semin. Hematol. 46, 371-377. doi: 10.1053/j.seminhematol.2009.07.001.
14. Camaschella, C. (2013). Treating iron overload. N. Engl. J. Med. 368, 2325-2327. doi: 10.1056/NEJMcibr1304338.
15. Crichton, R. (2001). Inorganic Biochemistry of Iron Metabolism From Molecular Mechanisms to Clinical Consequences, 2nd Edn. London: Wiley. .
16. Daar, S., Pathare, A., Nick, H., Kriemler-Krahn, U., Hmissi, A., Habr, D., et al. (2009). Reduction in labile plasma iron during treatment with deferasirox a once-daily oral iron chelator in heavily iron-overloaded patients with beta-thalassaemia. Eur. J. Haematol. 82, 454-457. doi: 10.1111/j.1600-0609.2008.01204.x.
17. Danjou, F., Cabantchik, Z. I., Origa, R., Moi, P., Marcias, M., Barella, S., et al. (2014). A decisional algorithm to start iron chelation in patients with beta thalassemia. Haematologica 99, e38-e40. doi: 10.3324/haematol.2013.098202.
18. Devireddy, L. R., Hart, D. O., Goetz, D. H., and Green, M. R. (2010). A mammalian siderophore synthesized by an enzyme with a bacterial homolog involved in enterobactin production. Cell 141, 1006-1017. doi: 10.1016/j.cell.2010.04.040.
19. Epsztejn, S., Kakhlon, O., Breuer, W., Glickstein, H., and Cabantchik, Z. I. (1997). A fluorescence assay for the labile iron pool (LIP) of mammalian cells. Anal. Biochem. 248, 31-40. doi: 10.1006/abio.1997.2126.
20. Esposito, B. P., Breuer, W., Sirankapracha, P., Pootrakul, P., Hershko, C., and Cabantchik, Z. I. (2003). Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 102, 2670-2677. doi: 10.1182/blood-2003-03-0807.
21. Esposito, B. P., Epsztejn, S., Breuer, W., and Cabantchik, Z. I. (2002). A review of fluorescence methods for assessing labile iron in cells and biological fluids. Anal. Biochem. 304, 1-18. doi: 10.1006/abio.2002.5611.
22. Evans, P. J., and Halliwell, B. (1994). Measurement of iron and copper in biological systems: bleomycin and copper-phenanthroline assays. Methods Enzymol. 233, 82-89. doi: 10.1016/S0076-6879(94)33010-7.
23. Evans, R. W., Rafique, R., Zarea, A., Rapisarda, C., Cammack, R., Evans, P. J., et al. (2008). Nature of non-transferrin-bound iron: studies on iron citrate complexes and thalassemic sera. J. Biol. Inorg. Chem. 13, 57-74. doi: 10.1007/s00775-007-0297-8.
24. Fleming, R. E., and Ponka, P. (2012). Iron overload in human disease. N. Engl. J. Med. 366, 348-359. doi: 10.1056/NEJMra1004967.
25. Glickstein, H., Ben-El, R. B., Link, G., Breuer, W., Konijn, A. M., Hershko, C., et al. (2006). Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood 108, 3195-3203. doi: 10.1182/blood-2006-05-020867.
26. Glickstein, H., El, R. B., Shvartsman, M., and Cabantchik, Z. I. (2005). Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood 106, 3242-3250. doi: 10.1182/blood-2005-02-0460.
27. Gosriwatana, I., Loreal, O., Lu, S., Brissot, P., Porter, J., and Hider, R. C. (1999). Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin. Anal. Biochem. 273, 212-220. doi: 10.1006/abio.1999.4216.
28. Graham, G., Bates, G. W., Rachmilewitz, E. A., and Hershko, C. (1979). Nonspecific serum iron in thalassemia: quantitation and chemical reactivity. Am. J. Hematol. 6, 207-217. doi: 10.1002/ajh.2830060305.
29. Greenberg, P. L., Koller, C. A., Cabantchik, Z. I., Warsi, G., Glynos, T., Paley, C., et al. (2010). Prospective assessment of effects on iron overload parameters of deferasirox therapy in patients with myelodysplastic syndromes. Leuk. Res. 34, 1560-1565. doi: 10.1016/j.leukres.2010.06.013.
30. Halliwell, B., Aruoma, O. I., Mufti, G., and Bomford, A. (1988). Bleomycin-detectable iron in serum from leukemic patients before and after chemotherapy. Therapeutic implications for treatment with oxidant-generating drugs. FEBS Lett. 241, 202-204. doi: 10.1016/0014-5793(88)81061-5.
31. Hershko, C., Graham, G., Bates, G. W., and Rachmilewitz, E. A. (1978). Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br. J. Haematol. 40, 255-263. doi: 10.1111/j.1365-2141.1978.tb03662.x.
32. Hershko, C., Link, G., Konijn, A. M., and Cabantchik, Z. I. (2005). Iron Chelation therapy. Curr. Hematol. Rep. 4, 110-116.
33. Hider, R. C., and Kong, X. L. (2011). Glutathione: a key component of the cytoplasmic labile iron pool. Biometals 24, 1179-1187. doi: 10.1007/s10534-011-9476-8.
34. Jacobs, A. (1977). An intracellular transit iron pool. Blood 50, 4331-4336. doi: 10.1002/9780470720325.ch5.
35. Jacobs, E. M., Hendriks, J. C., van Tits, B. L., Evans, P. J., Breuer, W., Liu, D. Y., et al. (2005). Results of an international round robin for the quantification of serum non-transferrin-bound iron: need for defining standardization and a clinically relevant isoform. Anal. Biochem. 341, 241-250. doi: 10.1016/j.ab.2005.03.008.
36. Kakhlon, O., Breuer, W., Munnich, A., and Cabantchik, Z. I. (2010). Iron relocation therapy for the treatment of diseases of regional iron accumulation. Rev. Can. J. Physiol. Pharmacol. 88, 187-196. doi: 10.1139/Y09-128.
37. Kakhlon, O., and Cabantchik, Z. I. (2002). The labile iron pool: characterization, measurement, and participation in cellular processes. Free Radic. Biol. Med. 33, 1037-1046. doi: 10.1016/S0891-5849(02)01006-7.
38. Kakhlon, O., Gruenbaum, Y., and Cabantchik, Z. I. (2001). Repression of ferritin expression increases the labile iron pool and oxidative stress and short-term growth of human erythroleukemia cells. Blood 97, 2863-2871. doi: 10.1182/blood.V97.9.2863.
39. Kakhlon, O., Manning, H., Breuer, W., Melamed-Book, N., Lu, C., Cortopassi, G., et al. (2008). Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation. Blood 112, 5219-5227. doi: 10.1182/blood-2008-06-161919.
40. Kolb, A. M., Smit, N. P., Lentz-Ljuboje, R., Osanto, S., and van Pelt, J. (2009). Non-transferrin bound iron measurement is influenced by chelator concentration. Anal. Biochem. 385, 13-19. doi: 10.1016/j.ab.2008.11.003.
41. Kruszewski, M. (2003). Labile iron pool: the main determinant of cellular response to oxidative stress. Mutat. Res. 29, 81-92. doi: 10.1016/j.mrfmmm.2003.08.004.
42. Le Lan, C., Loréal, O., Cohen, T., Ropert, M., Glickstein, H., and Lainé, F. (2005). Redox active plasma iron in C282Y/C282Y hemochromatosis. Blood 105, 4527-4531. doi: 10.1182/blood-2004-09-3468.
43. Levi, S., and Rovidac, E. (2009). The role of iron in mitochondrial function. Biochim. Biophys. Acta 1790, 629-636. doi: 10.1016/j.bbagen.2008.09.008.
44. Li-Hsuan Huang, M., Lane, D. J. R., and Richardson, D. R. (2011). The mitochondrion as a modulator of iron metabolism and its role in disease. Antioxid. Redox Signal. 15, 3003-3019. doi: 10.1089/ars.2011.3921.
45. Linder, M. C., Moriya, M., Whon, A. M., Kassa, A., and Gilley, C. (2006). Vesicular transport of Fe and interaction with other metal ions in polarized Caco2 Cell monolayers. Biol. Res. 39, 143-156. doi: 10.4067/S0716-97602006000100016.
46. Liuzzi, J. P., Aydemir, F., Nam, H., Knutson, M. D., and Cousins, R. J. (2006). Zip14 (Slc39a14) mediates non-transferrin-bound iron uptake into cells. Proc. Natl. Acad. Sci. U.S.A. 103, 13612-13617. doi: 10.1073/pnas.0606424103.
47. Ma, Y., DeGroot, H., Liu, Z., Hider, R., and Petrat, F. (2006). Chelation and determination of labile iron in primary hepatocytes by pyridinone fluorescent probes. Biochem. J. 395, 49-55. doi: 10.1042/BJ20051496.
48. Ma, Y., Zhou, T., Kong, X., and Hider, R. C. (2012). Chelating agents for the treatment of systemic iron overload. Rev. Curr. Med. Chem. 19, 2816-2827. doi: 10.2174/092986712800609724.
49. Núñez, M. T., Álvarez-Hernández, X., Smith, M., Tapia, V., and Glass, J. (1994). Role of redox systems on Fe3+ uptake by transformed human intestinal epithelial (Caco-2) cells. Am. J. Physiol. 267, C1582-C1588.
50. Núñez, M. T., Núñez-Millacura, C., Beltrán, M., Tapia, V., and Álvarez-Hernández, X. (1999). Apotransferrin and holotransferrin undergo different endocytic cycles in intestinal epithelia (Caco-2) cells. J. Biol. Chem. 272, 19425-19428. doi: 10.1074/jbc.272.31.19425.
51. 2+ channels in iron transport and iron-overload cardiomyopathy. J. Mol. Med. 84, 349-364. doi: 10.1007/s00109-005-0029-x.
52. Petrat, F., de Groot, H., Sustmann, R., and Rauen, U. (2002). The chelatable iron pool in living cells: a methodically defined quantity. Biol. Chem. 383, 489-502. doi: 10.1515/BC.2002.051.
53. Picard, V., Epsztejn, S., Santambrogio, P., Cabantchik, Z. I., and Beaumont, C. (1998). Role of ferritin in the control of the labile iron pool in murine erythroleukemia cells. J. Biol. Chem. 273, 15382-15386. doi: 10.1074/jbc.273.25.15382.
54. Pietrangelo, A. (2007). Iron chelation beyond transfusion iron overload. Am. J. Hematol. 82, 1142-1146. doi: 10.1002/ajh.21101.
55. Pootrakul, P., Breuer, W., Sametband, M., Sirankapracha, P., Hershko, C., and Cabantchik, Z. I. (2004). Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron overloaded beta-thalassaemia/HbE patients treated with an oral chelator. Blood 104, 1504-1510. doi: 10.1182/blood-2004-02-0630.
56. Porter, J. B. (2009). Pathophysiology of transfusional iron overload: contrasting patterns in thalassemia major and sickle cell disease Hemoglobin 33, S37-S45. doi: 10.3109/03630260903346627.
57. Prus, E., and Fibach, E. (2008a). Flow cytometry measurement of the labile iron pool in human hematopoietic cells. Cytometry 73, 22-27. doi: 10.1002/cyto.a.20491.
58. Prus, E., and Fibach, E. (2008b). The labile iron pool in human erythroid cells. Br. J. Haematol. 142, 301-307. doi: 10.1111/j.1365-2141.2008.07192.x.
59. Rauen, U., Springer, A., Weisheit, D., Petrat, F., Korth, H. G., de Groot, H., et al. (2007). Assessment of chelatable mitochondrial iron by using mitochondrion-selective fluorescent iron indicators with different iron-binding affinities. Chem. Biochem. 8, 341-352. doi: 10.1002/cbic.200600311.
60. Rouault, T. A. (2006). The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat. Chem. Biol. 8, 406-414. doi: 10.1038/nchembio807.
61. Rouault, T. A. (2012). Biogenesis of iron-sulfur clusters in mammalian cells: new insights and relevance to human disease. Dis. Model. Mech. 5, 155-164. doi: 10.1242/dmm.009019.
62. Sheftel, A. D., Zhang, A. S., Brown, C., Shirihai, O. S., and Ponka, P. (2007). Direct interorganellar transfer of iron from endosome to mitochondrion. Blood 110, 125-132. doi: 10.1182/blood-2007-01-068148.
63. Shi, H., Bencze, K. Z., Stemmler, T. L., and Philpott, C. C. (2008). A cytosolic iron chaperone that delivers iron to ferritin. Science 32, 1207-1210. doi: 10.1126/science.1157643.
64. Shvartsman, M., and Cabantchik, Z. I. (2012). Intracellular iron trafficking: role of cytosolic ligands. Biometals 25, 711-723. doi: 10.1007/s10534-012-9529-7.
65. Shvartsman, M., Fibach, E., and Cabantchik, Z. I. (2010). Transferrin-iron routing to the cytosol and mitochondria as studied by live and real-time fluorescence. Biochem. J. 429, 185-193. doi: 10.1042/BJ20100213.
66. Shvartsman, M., Kikkeri, A., Shanzer, A., and Cabantchik, Z. I. (2007). Iron accesses mitochondria from a cytosolic pool of non-labile iron. Biological and clinical implications. Am. J. Physiol. Cell Physiol. 293, C1383-C1394. doi: 10.1152/ajpcell.00054.2007.
67. Silva, A. M., and Hider, R. C. (2009). Influence of non-enzymatic post-translation modifications on the ability of human serum albumin to bind iron Implications for non-transferrin-bound iron speciation. Biochim. Biophys. Acta 1794, 1449-1458. doi: 10.1016/j.bbapap.2009.06.003.
68. Singh, S., Hider, R. C., and Porter, J. B. (1990). A direct method for quantification of non-transferrin-bound iron. Anal. Biochem. 86, 320-323. doi: 10.1016/0003-2697(90)90088-Q.
69. Sohn, Y. S., Breuer, W., Munnich, A., and Cabantchik, Z. I. (2008). Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications. Blood 111, 1690-1699. doi: 10.1182/blood-2007-07-102335.
70. Sohn, Y. S., Ghoti, H., Breuer, W., Rachmilewitz, E. A., Attar, S., Weiss, G., et al. (2012). The role of endocytic pathways in cellular uptake of plasma non-transferrin iron. Haematologica 97, 670-678. doi: 10.3324/haematol.2011.054858.
71. Sohn, Y. S., Mitterstiller, A. M., Breuer, W., Weiss, G., and Cabantchik, Z. I. (2011). Rescuing iron overloaded macrophages by conservative relocation of accumulated metal. Br. J. Pharmacol. 164, 406-418. doi: 10.1111/j.1476-5381.2010.01120.x.
72. Weaver, J., and Pollack, S. (1989). Low-Mr iron isolated from guinea pig reticulocytes as AMP-Fe and ATP-Fe complexes. Biochem. J. 26, 787-790.
73. Zanninelli, G., Breuer, W., and Cabantchik, Z. I. (2009). Daily labile plasma iron as an indicator of chelator activity in Thalassaemia major patients. Br. J. Haematol. 147, 744-751. doi: 10.1111/j.1365-2141.2009.07907.x.
74. Zhang, A. S., Sheftel, A. D., and Ponka, P. (2005). Intracellular kinetics of iron in reticulocytes: evidence for endosome involvement in iron targeting to mitochondria. Blood 105, 368-375. doi: 10.1182/blood-2004-06-2226.